Stockreport

Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF The deal gives Royalty Pharma a low single-digit royalty on Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh [Read more]